Incyte Corporation (INCY), headquartered in Wilmington, Delaware, discovers, develops, and commercializes therapeutics for hematology/oncology, as well as inflammation and autoimmunity areas. Valued ...
As of December 6, 2025, the average one-year price target for Incyte is $96.26/share. The forecasts range from a low of $70.70 to a high of $131.25. The average price target represents a decrease of 6 ...
We recently published Wall Street Can’t Keep up With These 10 Crushing Stocks; 6 at Fresh Record Highs. Incyte Corp. (NASDAQ:INCY) is one of the best-performing on Monday. Incyte extended its winning ...
Hosted on MSN
Wells Fargo Upgrades Incyte (INCY)
Fintel reports that on August 6, 2025, Wells Fargo upgraded their outlook for Incyte (NasdaqGS:INCY) from Equal-Weight to Overweight. Analyst Price Forecast Suggests 6.78% Upside As of August 6, 2025, ...
10monon MSN
Incyte Corporation (INCY): Among the Best Biotech Stocks to Buy According to Billionaires
We recently compiled a list of the 15 Best Biotech Stocks to Buy According to Billionaires. In this article, we are going to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results